Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13541
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurrell, Louise Men
dc.contributor.authorFarina, N Ken
dc.contributor.authorRisvanis, Johnen
dc.contributor.authorWoollard, Den
dc.contributor.authorCasely, Den
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-16T03:25:00Z
dc.date.available2015-05-16T03:25:00Z
dc.date.issued1997-07-01en
dc.identifier.citationClinical Science 1997; 93(1): 43-50en
dc.identifier.govdoc9279202en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13541en
dc.description.abstract1. Inhibition of neutral endopeptidase (NEP), the degradative enzyme for atrial natriuretic peptide, was studied in vitro and in vivo using a previously characterized NEP inhibitor radioligand, 125I-labelled RB104. 2. SCH 42354, the active di-acid of the ethylester prodrug, SCH 42495, caused a concentration-dependent displacement of 125I-labelled RB104 from rat renal NEP. The concentration of SCH 42354 that displaced 50% of radioligand bound to the enzyme NEP (IC50) was 3.3 +/- 0.1 nmol/l (mean +/- SEM). Enalaprilat, an angiotensin converting enzyme inhibitor, did not displace 125I-labelled RB104 in concentrations up to 10 mumol/l. 3. In adult normotensive Sprague-Dawley rats, oral SCH 42495 (3-300 mg/kg) caused significant inhibition of renal NEP (P < 0.001). SCH 42495 had no effect on renal or plasma angiotensin converting enzyme activity, but high-dose SCH 42495 (300 mg/kg) caused a significant increase in plasma renin activity (P < 0.01). 4. In a time course study, oral SCH 42495 (30 mg/kg) caused rapid (within 30 min) and significant inhibition of renal NEP for up to 48 h (P < 0.001). No changes in plasma atrial natriuretic peptide or plasma angiotensin converting enzyme activity were seen. 5. These data provide evidence that short-term administration of the NEP inhibitor SCH 42495 results in inhibition of renal NEP and does not inhibit the circulating or the tissue renin-angiotensin system. The NEP inhibitor radioligand 125I-labelled RB104, is a useful tool to study tissue NEP inhibition after administration of NEP inhibitors.en
dc.language.isoenen
dc.subject.otherAdministration, Oralen
dc.subject.otherAnimalsen
dc.subject.otherAtrial Natriuretic Factor.metabolismen
dc.subject.otherBinding, Competitiveen
dc.subject.otherDose-Response Relationship, Drugen
dc.subject.otherFemaleen
dc.subject.otherIodine Radioisotopes.diagnostic useen
dc.subject.otherIodobenzenes.administration & dosage.pharmacologyen
dc.subject.otherKidney.drug effects.enzymologyen
dc.subject.otherMethionine.administration & dosage.analogs & derivatives.pharmacologyen
dc.subject.otherNeprilysin.antagonists & inhibitorsen
dc.subject.otherPeptidyl-Dipeptidase A.blooden
dc.subject.otherProdrugs.administration & dosage.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherRenin.blooden
dc.subject.otherTime Factorsen
dc.subject.othergamma-Aminobutyric Acid.administration & dosage.analogs & derivatives.pharmacologyen
dc.titleInhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Scienceen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.description.pages43-50en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9279202en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.